Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MELK | Q14680 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045609 | 0.77 | TDP1 (0.46) | THRBHPGDALDH1A1CYP3A4KMT2A | |
| SCHEMBL15905413 | 0.74 | RORC (0.44) | TYK2HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL1029756 | 0.69 | CYP3A4 (0.58) | THRBHPGDALDH1A1CYP3A4BACE1 | |
| SCHEMBL30606587 | 0.68 | KDM2B (0.46) | HSD11B1HPGDMGLLKMT2ATSHR | |
| SCHEMBL26599052 | 0.68 | KDM2B (0.46) | HSD11B1HPGDMGLLKMT2ATSHR | |
| SCHEMBL23580096 | 0.67 | TYK2 (0.39) | TYK2HSD11B1MELKCYP3A4MGLL | |
| SCHEMBL30461435 | 0.67 | HPGD (0.42) | HPGDMELKALDH1A1MGLLKMT2A | |
| SCHEMBL25253119 | 0.67 | HPGD (0.42) | HPGDMELKALDH1A1MGLLKMT2A | |
| SCHEMBL12202677 | 0.66 | SMN1; SMN2 (0.44) | HSD11B1HPGDALDH1A1MGLLKMT2A | |
| Hydrochloric Acid SCHEMBL30461452 | 0.66 | HPGD (0.41) | HPGDMELKALDH1A1MGLLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948149-B1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20240189260-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-117045653-A | Diseases and treatments associated with toxic aldehydes | 奥尔德拉医疗公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111135171-B | Diseases and treatments associated with toxic aldehydes | 奥尔德拉医疗公司 | 2023-09-08 | — | — | CN | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-114085236-A | Aldehyde conjugates and uses thereof | 奥尔德拉医疗公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3337470-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | Aldeyra Therapeutics, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2017-08-24 | — | — | US | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2017035082-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| EP-2948436-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | Aldeyra Therapeutics, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2948149-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | Aldeyra Therapeutics, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| WO-2014116836-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014116593-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6D, PDE6A | TYK2 4567/4885HSD11B1 1313/4885THRB 2028/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | TYK2 2800/4885HSD11B1 1223/4885THRB 4627/4885 |
| US-20240189260-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | TYK2 3739/4885HSD11B1 846/4885THRB 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.